Insights into Bifidobacterium infantis and Complementary Feeding Guidelines
The World Health Organization (WHO) and UNICEF strongly recommend initiating breast-feeding within the first hour of birth and maintaining exclusive breast-feeding for the first six months of life. However, despite these global health guidelines, fewer than half of infants under six months are exclusively breast-fed. This early developmental window is critical for the establishment of a healthy gut microbiota, particularly the colonization of Bifidobacterium species, which plays a foundational role in supporting lifelong immune, metabolic, and digestive health
In a double-blind, randomized, placebo-controlled clinical trial involving 110 healthy-term infants, researchers investigated the safety and efficacy of early probiotic supplementation using Bifidobacterium longum ssp. infantis M‑63. Infants received daily supplementation of B. infantis M‑63 (1 × 10⁹ CFU) from ≤ 7 days old to 3 months of age. The study assessed fecal microbiota composition, stool pH, short-chain fatty acid (SCFA) production, secretory IgA levels, and stool quality. Key findings revealed a significantly higher abundance of Bifidobacterium in the probiotic group, along with increased acetic acid and IgA levels, and a notable reduction in stool pH. Infants supplemented with B. infantis M‑63 also experienced fewer episodes of defecation and watery stools. Importantly, there were no adverse events linked to the probiotic, and its efficacy was positively correlated with breast-feeding frequency.
These results confirm that early supplementation with B. infantis M‑63 is both safe and beneficial for establishing a Bifidobacterium-dominant gut microbiota during this crucial stage of infant development. Knowing that many women with busy lives may not be able to exclusively breast-feed for the full six months, adding a high-quality probiotic containing Bifidobacterium is a must for supporting the future health and resilience of their infants.